Alzheimer's Disease and Dementia
Featured Topics
Lead story
Other featured articles
-
Prospects for Future Advances in Alzheimer’s Disease
This paper revisits expert predictions for future advances in Alzheimer’s disease (AD) made in 2001 and projects future breakthroughs over the next 20 years.
Posted in -
The Value of Delaying Alzheimer’s Disease Onset
Models show that the number of patients will more than double in 40 years, and costs associated with their care will nearly quintuple.
Posted in -
Pilot Funding Available for Researchers of Alzheimer’s, Aging
Pilot funding amounts range from $25,000 to up to $45,000. An informational session on the application process will be held over zoom on Thursday, December 9, 2021, at 10:00 a.m. pacific.
Posted in -
Schaeffer Center P30 Pilots Info Session
Join Schaeffer Center for a joint info session on pilot opportunities ($25K-$45K) through our NIH-funded P30 centers.
Posted in
About this section
Even small delays in the onset of Alzheimer's disease and dementia could have significant impacts for the patient, their family and caregivers, and the healthcare system more broadly. The Schaeffer Center's microsimulation models demonstrate there may be preventive measures we can take now to shape the nation's future health.
OUR EXPERTS ON ALZHEIMER'S DISEASE AND DEMENTIA PREVENTION
Our Work In Alzheimer's Disease and Dementia
-
Applying for the 2022-2023 CeASES-ADRD Pilot Award
All application information must be submitted by the close of business on Friday, February 5, 2021.
-
The Costs of Developing Treatments for Alzheimer’s Disease: A Retrospective Exploration
With the exception of the recent accelerated approval of aducanumab, in over 26 years of research and development (R&D) investment in Alzheimer’s disease (AD), only five novel drugs—all for symptomatic treatment only—have reached FDA approval. Here, we estimate the costs of AD drug development during this period in the private sector.
Categorized in -
NAM Expert Briefing on Behavioral and Social Science Research Questions Raised By the Use of Biomarkers for Alzheimer’s Disease Diagnostics
On June 28 and 29, 2021, the National Academies of Sciences, Engineering, and Medicine convened an expert meeting that addressed behavioral and social science research questions raised by the use of biomarkers and other measures for pre-clinical AD/ADRD diagnosis
-
NAS Report Outlines Priorities for the Next Ten Years of Alzheimer’s Research
Julie Zissimopoulos participated on the committee tasked with developing the research agenda.
-
Clinical Outcome Measure Crosswalks in Alzheimer’s Disease: A Systematic Review
A key challenge in studies that model outcomes, disease progression, and cost-effectiveness of existing and emerging dementia treatments is the lack of conversion criteria to translate, or ‘crosswalk’, scores on multiple measurement scales.
Categorized in -
Leveraging Behavioral Sciences for Dementia Care
Insights from the behavioral sciences may help doctors detect dementia earlier and develop more insightful care plans.